Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Transmission and prevention news

Show

From To
Gilead Ignored HIV Groups Before Failed Bid To Have PrEP Subsidised In Australia

A drug manufacturer failed to take the advice of top HIV/AIDS organisations when it made a submission for a highly effective HIV prevention drug to be subsidised by the government, those organisations say.

Published
22 hours ago
From
BuzzFeed
Neglect of infectious diseases in prisons highlighted at AIDS 2016

“Prisoners are among the most neglected of the key populations; they bear higher burdens of HIV, viral hepatitis and tuberculosis than in the communities from which they

Published
25 August 2016
By
Theo Smart
Hysteria about drugs and harm minimisation. It's always the same old story

"No matter how impressive the evidence of benefits, or how weak the evidence of serious side effects or how badly a strategy is needed, new harm reduction strategies are always greeted the same way: with relentless hostility. Debates about harm reduction always follow the same pattern. Hysterical fears are confidently asserted as if proven beyond doubt while potential benefits, often based on considerable research and experience, are dismissed or ignored."

Published
23 August 2016
From
The Guardian
Having Sex With Poz Men Helped Kick My Fear of HIV

The fear of contracting HIV has run my life for what feels like forever, and I’m not willing to let it control me any longer.

Published
23 August 2016
From
The Advocate
European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for once-daily Truvada® (emtricitabine 200 mg/tenofovir disoproxil 245 mg; FTC/TDF) in combination with safer-sex practices to reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk, a strategy known as pre-exposure prophylaxis, or PrEP.

Published
22 August 2016
From
Gilead press release
Make your voice heard on PrEP in England – take part in the PrEP public consultation

PrEPster, along with NAT and THT, and other organisations in the United4PrEP coalition is urging individuals and institutions to take part in the NHS England PrEP consultation. The results from the consultation will be considered by the NHS England committee (CPAG) that makes the final decision on PrEP. Together, we’ve produced toolkits that assist individuals and organisations in responding to the consultation, along with sample responses.

Published
22 August 2016
From
Prepster
Understanding the Rationale for the HVTN 702 Trial

What have scientists learned that helped inform the design of this pivotal AIDS vaccine study in South Africa?

Published
22 August 2016
From
Vax Report
HIV prevention drug Truvada won't be subsidised in Australia

Truvada, an expensive breakthrough drug that prevents people from getting HIV won't be funded by taxpayers in Australia this year, the nation's drug funding panel has ruled. A Department of Health spokeswoman said the PBAC understood "this is an important new prevention medication for HIV", but decided the price set by the drug's sponsor, Gilead Sciences, was too high and a proposal to limit subsidy to a small subset of the "at risk" group was not feasible. "In its deliberations the PBAC indicated a substantial price reduction would be needed to make Truvada available for PrEP for the whole 'at risk' population, but noted that Truvada for PrEP could represent value for money in the broader population at a substantially lower price," the spokeswoman said.

Published
19 August 2016
From
Sydney Morning Herald
Nottinghamshire dentist Desmond D'Mello struck off by General Dental Council

A dentist who sparked "the biggest NHS patient recall in history" is struck off.

Published
19 August 2016
From
BBC Health
A Look Inside Cape Town’s Only Harm Reduction Project

Last month, I was lucky enough to take part in the 21st International AIDS Conference (AIDS 2016) in Durban, South Africa. Though harm reduction, and the rights of people who use drugs were almost non-existent on the conference agenda, I managed to visit a harm reduction project working in Cape Town, South Africa and see what services are available in the country.

Published
18 August 2016
From
Talking Drugs
← First12345...492Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close